+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nuclear Pharmacy - Global Strategic Business Report

  • PDF Icon

    Report

  • 275 Pages
  • August 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6106412
The global market for Nuclear Pharmacy was estimated at US$6.1 Billion in 2024 and is projected to reach US$8.6 Billion by 2030, growing at a CAGR of 5.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Nuclear Pharmacy market.

Global Nuclear Pharmacy Market - Key Trends & Drivers Summarized

Why Is Nuclear Pharmacy Gaining Prominence in Modern Healthcare?

Nuclear pharmacy is emerging as a critical component of diagnostic and therapeutic medicine due to its role in preparing radiopharmaceuticals used in nuclear imaging and targeted treatments. As demand rises for precision diagnostics in oncology, cardiology, and neurology, nuclear pharmacies are becoming essential in supplying time-sensitive, patient-specific radiotracers to imaging centers and hospitals. These compounds help visualize biological processes at the molecular level, enabling early detection of disease and more accurate monitoring of treatment response.

In addition to diagnostic imaging, nuclear pharmacy plays a growing role in theranostics-where therapeutic and diagnostic capabilities are combined in a single radiopharmaceutical. This integration supports a more personalized approach to patient care, where specific isotopes can be used to both identify and treat tumors. As healthcare shifts toward minimally invasive and targeted interventions, nuclear pharmacy is expected to play an increasingly central role in clinical workflows.

How Are Advancements in Radiopharmaceuticals and Isotope Production Driving Growth?

The development of new radiopharmaceuticals is expanding the scope of nuclear pharmacy beyond conventional tracers such as technetium-99m and fluorine-18. Novel agents are being designed for more specific disease targeting, including peptides and antibodies labeled with isotopes like lutetium-177 and gallium-68. These compounds are being used in the management of prostate cancer, neuroendocrine tumors, and other hard-to-treat conditions, creating opportunities for specialized nuclear pharmacy operations.

Isotope production is also undergoing transformation. Cyclotron and generator-based production techniques are improving reliability and local availability of short-lived isotopes, reducing dependency on aging nuclear reactors. Automated synthesis modules and quality control systems are improving radiopharmaceutical preparation, standardizing dosage, and reducing exposure risks to pharmacy personnel. These innovations are supporting faster, safer, and more scalable delivery of radiotracers to healthcare providers.

What Structural and Regulatory Factors Influence Market Expansion?

Nuclear pharmacy operates under strict regulatory controls given the handling of radioactive materials. Compliance with national and international standards requires specialized infrastructure, staff training, and licensing, which limits the number of facilities that can operate at scale. However, growth in centralized and networked radiopharmacies is helping healthcare systems improve logistics, reduce waste, and ensure on-time delivery of radiopharmaceuticals with short half-lives.

The rise of outpatient diagnostic centers and integrated care networks is further influencing nuclear pharmacy expansion. Many health systems are investing in in-house or partnered radiopharmacy capabilities to reduce reliance on external suppliers. Public and private funding in cancer care, coupled with regulatory fast-tracking of novel radiotherapeutics, is strengthening supply chains and accelerating market development. Partnerships between pharmaceutical companies, isotope producers, and healthcare providers are also emerging to meet rising clinical demand.

Growth in the nuclear pharmacy market is driven by several factors.

Increased use of nuclear imaging and theranostics in oncology, cardiology, and neurology is boosting demand for timely, high-quality radiopharmaceuticals. Development of novel isotopes and targeted radiotracers is expanding the range of clinical applications. Advances in automated synthesis and isotope production technologies are improving operational efficiency and safety. Expansion of centralized radiopharmacy models is enabling wider access to time-sensitive diagnostic agents. Regulatory support for new radiotherapeutics and growing investment in personalized medicine are reinforcing the integration of nuclear pharmacy into standard care protocols. These factors are collectively shaping a strong growth trajectory for the nuclear pharmacy market globally.

Scope Of Study:

The report analyzes the Nuclear Pharmacy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Type (Institutional Type, Commercial Type); Purpose (Diagnostic, Therapeutic)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Institutional Type segment, which is expected to reach US$4.8 Billion by 2030 with a CAGR of a 4.5%. The Commercial Type segment is also set to grow at 7.7% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $1.7 Billion in 2024, and China, forecasted to grow at an impressive 9.0% CAGR to reach $1.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Nuclear Pharmacy Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Nuclear Pharmacy Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Nuclear Pharmacy Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Advanced Accelerator Applications (AAA), Bayer AG (Radiopharma division), Bracco Imaging S.p.A., Cardinal Health, Inc. (Nuclear Pharmacy), Curium Pharma and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 44 companies featured in this Nuclear Pharmacy market report include:

  • Advanced Accelerator Applications (AAA)
  • Bayer AG (Radiopharma division)
  • Bracco Imaging S.p.A.
  • Cardinal Health, Inc. (Nuclear Pharmacy)
  • Curium Pharma
  • Eczacibasi-Monrol Nuclear Products
  • Eckert & Ziegler (Radiopharma division)
  • GE HealthCare (Nuclear Pharmacy Services)
  • IBA Molecular Imaging
  • Jubilant Radiopharma (Jubilant DraxImage)
  • Lantheus Medical Imaging, Inc.
  • Mallinckrodt plc. (Nuclear Imaging)
  • NTP Radioisotopes SOC Ltd.
  • Nihon Medi-Physics Co., Ltd.
  • Nordion Inc. (Sotera Health)
  • Novartis (Advanced Accelerator Applications)
  • PharmaLogic Holdings Corp.
  • Siemens Healthineers
  • Shine Technologies (SHINE Medical)
  • Telix Pharmaceuticals Limited

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Nuclear Pharmacy - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Demand for Targeted Diagnostic Imaging Drives Growth in Nuclear Pharmacy Services
  • Expansion of PET and SPECT Imaging in Oncology, Cardiology, and Neurology Boosts Radiopharmaceutical Usage
  • Increased Availability of Short-Lived Isotopes Spurs Growth in Centralized and In-Hospital Nuclear Pharmacies
  • Advancements in Cyclotron and Generator Technologies Enhance On-Demand Radiotracer Production
  • Regulatory Approvals for New Radiolabeled Drugs Strengthen Market for Precision Diagnostic Tools
  • Shift Toward Personalized Medicine Throws the Spotlight on Radiotheranostics and Companion Diagnostics
  • Growing Use of Radiopharmaceuticals in Therapeutic Applications Expands Scope of Nuclear Pharmacy Operations
  • Integration of Automation and Robotics in Radiopharmacies Improves Accuracy, Safety, and Throughput
  • Expansion of Academic and Clinical Research Programs Fuels Demand for Custom Radiopharmaceutical Compounding
  • Rising Incidence of Chronic and Age-Related Diseases Accelerates Investment in Nuclear Imaging Infrastructure
  • Improvements in Cold-Chain Logistics and Dose Scheduling Support Wider Distribution of Time-Sensitive Isotopes
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Nuclear Pharmacy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Nuclear Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Institutional Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Institutional Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Institutional Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Commercial Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Commercial Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Commercial Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Therapeutic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 17: USA Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 18: USA Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: USA 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
  • TABLE 20: USA Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 21: USA Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: USA 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
CANADA
  • TABLE 23: Canada Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 24: Canada Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: Canada 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
  • TABLE 26: Canada Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Canada Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: Canada 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
JAPAN
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 29: Japan Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: Japan Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: Japan 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
  • TABLE 32: Japan Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Japan Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: Japan 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
CHINA
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 35: China Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: China Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: China 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
  • TABLE 38: China Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: China Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: China 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
EUROPE
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 41: Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: Europe Historic Review for Nuclear Pharmacy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: Europe 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 44: Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Europe Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: Europe 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
  • TABLE 47: Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Europe Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Europe 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
FRANCE
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 50: France Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: France Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: France 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
  • TABLE 53: France Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: France Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: France 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
GERMANY
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 56: Germany Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Germany Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Germany 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
  • TABLE 59: Germany Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Germany Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Germany 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
ITALY
  • TABLE 62: Italy Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Italy Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Italy 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
  • TABLE 65: Italy Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Italy Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Italy 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
UNITED KINGDOM
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 68: UK Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: UK Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: UK 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
  • TABLE 71: UK Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: UK Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: UK 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
SPAIN
  • TABLE 74: Spain Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Spain Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Spain 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
  • TABLE 77: Spain Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Spain Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Spain 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
RUSSIA
  • TABLE 80: Russia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Russia Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Russia 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
  • TABLE 83: Russia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Russia Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Russia 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
REST OF EUROPE
  • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Rest of Europe Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Rest of Europe 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
  • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Rest of Europe Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Rest of Europe 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
ASIA-PACIFIC
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 93: Asia-Pacific Historic Review for Nuclear Pharmacy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Asia-Pacific Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
  • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Asia-Pacific Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
AUSTRALIA
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Advanced Accelerator Applications (AAA)
  • Bayer AG (Radiopharma division)
  • Bracco Imaging S.p.A.
  • Cardinal Health, Inc. (Nuclear Pharmacy)
  • Curium Pharma
  • Eczacibasi-Monrol Nuclear Products
  • Eckert & Ziegler (Radiopharma division)
  • GE HealthCare (Nuclear Pharmacy Services)
  • IBA Molecular Imaging
  • Jubilant Radiopharma (Jubilant DraxImage)
  • Lantheus Medical Imaging, Inc.
  • Mallinckrodt plc. (Nuclear Imaging)
  • NTP Radioisotopes SOC Ltd.
  • Nihon Medi-Physics Co., Ltd.
  • Nordion Inc. (Sotera Health)
  • Novartis (Advanced Accelerator Applications)
  • PharmaLogic Holdings Corp.
  • Siemens Healthineers
  • Shine Technologies (SHINE Medical)
  • Telix Pharmaceuticals Limited

Table Information